Antisoma divests failed anti-tumour MAb to Biothera as wind-down continues
This article was originally published in Scrip
Executive Summary
Antisoma's desperate attempts to squeeze out what money it can from the remainder of its assets has resulted in Biothera acquiring the anti-cancer monoclonal antibody, AS1402, for undisclosed terms.